Our new article, "Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors", showcases recent work into the mechanism of action of AB1, an inhibitor with potent activity against Trypanosoma brucei bloodstream forms, Leishmania and Trypanosoma cruzi. 

For the course, Nathaniel Jones and Nicola Baker gave a practical demonstration of CRISPR-Cas9 editing in Leishmania.

 

Regarding the course, Professor Mottram said: “CRIPSR genome editing transforms how we identify and validate new drug targets for neglected tropical diseases, such as leishmaniasis. The workshop in Kolkata provided theoretical and hands-on training in Leishmania gene manipulation, allowing students to extend the technology into their own research programs.  The success of the workshops in Rio de Janeiro and Kolkata are inspiring us to hold further training for researchers from developing countries.”

Please reload

CII and Mottram group representation at WorldLeish 2017

Scientists at the University of York and Hull York Medical School have been awarded two new grants to tackle the parasitic disease leishmaniasis.

One drug can treat three deadly and neglected infections - Chagas disease, leishmaniasis and sleeping sickness.

Please reload

Department of Biology
University of York

Heslington, York, YO10 5DD, UK 

jmottramgroup@gmail.com

CII representation